Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-Cell Therapy in Newly Authorized Treatment Centers in the United States - Inovalon

Accepted for presentation at American Society of Hematology (ASH). Findings available upon request. Contact us for more information.

Previous PostMissed Opportunities for Pharmacist Intervention Among Medicare Fee-for-Service Beneficiaries With Myasthenia Gravis: A Real-World Claims Analysis
Next PostImpact of Depression on Outcomes and Treatment Patterns in Patients With Newly Diagnosed Epilepsy: A Retrospective Claims Analysis